Iodixanol
Iodixanol is a pharmaceutical drug with 17 clinical trials. Historical success rate of 53.8%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
12
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
46.7%
7 of 15 finished
53.3%
8 ended early
0
trials recruiting
17
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
Clinical Trials (17)
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
DynaCT in Preoperative Imaging Before Insertion of Stentgraft
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction
Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients
Isovue in Peripheral Digital Subtraction Angiography (DSA)
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
All 17 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 17